Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
スポンサーリンク
概要
- 論文の詳細を見る
- Japanese Pharmacological Societyの論文
- 2007-10-20
著者
-
Ohmi Takashi
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Ohmi Takashi
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
KOJIMA Midori
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
KATO Naoto
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
EDA Hiroyuki
Discovery Biology Research, Nagoya Laboratories, Pfizer Japan Inc.
-
UENO Yoshinobu
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
YAMAMOTO Mitsuko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
MORIGUCHI Yukiko
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
SHIMOZONO Rieki
Discovery Biology Research, Global Research & Development, Nagoya Laboratories, Pfizer Japan, Inc.
-
SUZUKI Sachiko
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer
-
MATSUURA Tomomi
Pharmacokinetics, Dynamics & Metabolism, Global Research & Development, Nagoya Laboratories, Pfizer
-
Kato Naoto
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Eda Hiroyuki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Kojima Midori
Discovery Biology Research Nagoya Laboratories Pfizer Japan Inc.
-
Suzuki Sachiko
関西学院大学 理工学部ナノバイオテクノロジー研究開発センター
-
Ueno Yoshinobu
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Shimozono Rieki
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Matsuura Tomomi
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
-
Moriguchi Yukiko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Yamamoto Mitsuko
Discovery Biology Research Global Research & Development Nagoya Laboratories Pfizer Japan Inc.
-
Suzuki Sachiko
Pharmacokinetics Dynamics & Metabolism Global Research & Development Nagoya Laboratories Pfi
関連論文
- Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against α-Fas-Induced Liver Injury in a Mouse Model
- Contribution of Active and Inactive States of the Human 5-HT_ Receptor to the Functional Activities of 5-HT_4-Receptor Agonists
- Orally-Administered Caspase Inhibitor PF-03491390 Is Retained in the Liver for Prolonged Periods With Low Systemic Exposure, Exerting a Hepatoprotective Effect Against .ALPHA.-Fas-Induced Liver Injury in a Mouse Model